MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle

Jinbao Guo1, Li Zhong2, Mohammad Reza Momeni3

  • 1Department of Thoracic Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. guojingbao@126.com.

Cell Biology and Toxicology
|September 16, 2024
PubMed

Insights

MicroRNA-155 (miR-155) drives gastrointestinal cancer progression and chemoresistance. Targeting miR-155, including exosomal miR-155, offers a promising therapeutic strategy for GI cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastrointestinal (GI) cancers cause significant global mortality, necessitating novel therapeutic strategies.
  • MicroRNAs (miRNAs), including microRNA-155 (miR-155), are key regulators in cancer development.
  • Abnormal miR-155 expression is linked to increased mortality in various cancers, particularly GI malignancies.

Purpose of the Study:

  • To provide a comprehensive review of miR-155's multifaceted roles in GI cancers.
  • To highlight miR-155's involvement in cancer progression, therapeutic resistance, and intercellular communication.
  • To discuss current and future therapeutic and diagnostic implications of targeting miR-155.

Main Methods:

  • Literature review of studies investigating miR-155 in GI cancers.
  • Analysis of miR-155's function in tumorigenesis, metastasis, and drug resistance.
  • Examination of exosomal miR-155 and its role in cancer microenvironment modulation.

Main Results:

  • miR-155 acts as an oncomiR in pancreatic, colon, and gastric cancers.
  • Exosomal miR-155 facilitates intercellular communication and promotes GI cancer progression.
  • miR-155 is implicated in chemoresistance and influences immune-related cells within the tumor microenvironment.

Conclusions:

  • miR-155 is a critical driver of GI cancer development and progression.
  • Targeting miR-155, including exosomal forms, presents a viable therapeutic avenue.
  • Further research into miR-155 inhibitors, circular RNAs, and clinical trials is warranted for GI cancer treatment.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K